Patent · US Active

Method of treating a subject suffering from end stage renal disease against cardiovascular disease

US8657775B2 · kind B2 · utility

1Cited by

0References

8Claims

0Family size

Assignee

Gambro Lundis AB · SE

Inventors

Colin Hutchison · Birmingham, GB
Paul Cockwell · Birmingham, GB
Hermann Gohl · Bisingen, DE
Bernd Krause · Liederbach, DE
Markus Storr · Echterdingen, DE

Key dates

Filing date	Sep 1, 2009
Grant date	Feb 25, 2014
Priority date	—
Expiry date	Sep 4, 2030

Classification

Technology area (CPC B)Performing Operations; Transporting
CPC primaryB01D2325/20
WIPO fieldChemical engineering
WIPO sectorChemistry

Abstract

The present invention relates to high cut-off hemodialysis membranes for the treatment of chronic hemodialysis (CHD) patients, with the potential to improve long-term survival of these patients by reducing the risk of cardiovascular disease, through down-regulation of monocyte activation in the blood. Monocytes are the major circulating blood cells involved in the progression of cardiovascular disease. High cut-off hemodialysis in chronic dialysis patients results in a sustained decrease in expression of monocyte cell-surface proteins that direct the movement of these cells from the blood to the walls of blood vessels, where they promote the progression of arterial disease (atherosclerosis) that leads to cardiovascular disease (CVD); heart disease, strokes and peripheral vascular disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.